Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Common Equity (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Common Equity readings, the most recent being $35.5 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 704.09% to $35.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $35.5 million, a 704.09% increase, with the full-year FY2025 number at $35.5 million, up 704.09% from a year prior.
  • Common Equity hit $35.5 million in Q4 2025 for Fennec Pharmaceuticals, up from -$4.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $35.5 million in Q4 2025 to a low of -$11.6 million in Q4 2023.
  • Median Common Equity over the past 5 years was -$2.0 million (2022), compared with a mean of $3.6 million.
  • Biggest five-year swings in Common Equity: crashed 475.84% in 2023 and later skyrocketed 704.09% in 2025.
  • Fennec Pharmaceuticals' Common Equity stood at $15.8 million in 2021, then crashed by 116.29% to -$2.6 million in 2022, then plummeted by 352.39% to -$11.6 million in 2023, then soared by 49.48% to -$5.9 million in 2024, then skyrocketed by 704.09% to $35.5 million in 2025.
  • The last three reported values for Common Equity were $35.5 million (Q4 2025), -$4.5 million (Q3 2025), and -$7.5 million (Q2 2025) per Business Quant data.